A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
NCT07118878
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Fibrostenotic Crohn's Disease
Interventions
DRUG:
AGMB-129
OTHER:
Placebo
Sponsor
Agomab Spain S.L.U.